Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Journal of Biological Chemistry|January 22, 2015
Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epitheliaEdward J Richards, Gu Zhang, Zhu-Peng Li, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|August 2, 2014
Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009Ling-Bin Du, Hui-Zhang Li, Xiang-Hui Wang, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|June 11, 2014
Identifying EGFR mutations from SCLC patient plasma by mutant-enriched liquidchip technologyHong-Yang Lu, Zhen-Yi Lu, Qiao-Yuan Cheng, et al.
Zhonghua Yi Xue Za Zhi|July 12, 2012
[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis]Hong YANG, Jian-hua FU, Meng-zhong LIU, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2019
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II StudyWen-Zhao Zhong, Ke-Neng Chen, Chun Chen, et al.
Signal Transduction and Targeted Therapy|February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trialWen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
The Lancet. Oncology|November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Lung Cancer (Amsterdam, Netherlands)|November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) studyJian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Pageof 8